



# Nystatin Powder

## Therapeutical category:

Polyene antibiotic with antifungal activity for oral use and topical use

## Characteristics:

A crystalline powder

## Applications:

The product is suitable for the manufacture of different dosage forms, such as topical emulsions, ointments, tablets and vaginal tablets, after the addition of the appropriate excipients.



Quality



Reliability



Sustainability



## Key parameters: Nystatin Powder

Pharmacopeia quality	USP, EP	
Regulatory information	USA: FDA EU: EDQM Italy: AIFA	Canada: HC Australia: TGA Japan: PMDA
Appearance	A yellow or slightly brownish powder	
Potency	≥ 5000 IU/mg (EP) ≥ 5500 U/mg (USP)	
Loss on drying	≤ 5.0%	
Composition (by HPLC)	Nystatin A1: ≥ 85% Any other compound: ≤ 4.0%	
Residual solvents	Acetone: ≤ 0.5% (EP) Acetone: ≤ 0.20% (USP) Methylisobutylketone: ≤ 0.05%	
Shelf-life	3 years in the original packaging under storage conditions	
Batch size	Approximately 200 kg	
Storage conditions	Below 25°C, protected from light and moisture	
Packaging	Primary packaging: polyethylene bag	
	Secondary packaging: thermo-sealed multilayer aluminum polyethylene bag	
	Outer packaging: corrugated box	
	Fixed quantity of the product (16.84 kg) equivalent to the desired total potency is packed in each box (103 BoIU for EP or 105 BoU for the USP grade product)	

### Contact and information

For more information, please visit [www.centrient.com](http://www.centrient.com) or e-mail: [info@centrient.com](mailto:info@centrient.com) or contact us at one of the addresses below:

Rotterdam (HQ)  
[sales@centrient.com](mailto:sales@centrient.com)

Europe/North America  
Delft, The Netherlands  
[sales.ea@centrient.com](mailto:sales.ea@centrient.com)

Asia Pacific / Middle East / Africa  
Gurgaon, India  
[sales.amea@centrient.com](mailto:sales.amea@centrient.com)

China  
Beijing, P.R. China  
[sales.china@centrient.com](mailto:sales.china@centrient.com)

Mexico & Latin America  
Ramos Arizpe, Mexico  
[sales.mla@centrient.com](mailto:sales.mla@centrient.com)

Copyright © 2019 Centrient Pharmaceuticals. All rights reserved. Although diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein can be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor can it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement.

The content of this document is subject to change without further notice. Please contact us for the latest version of this document or further information. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions like the Bolar provisions in the US and 2004/27/EC in Europe.  
VAPFS 2019